Therapeutics, based in Southern California, has developed environmentally friendly solutions for the sustainable manufacturing of foods and active ingredients through precision fermentation.
The biosynthesis company, which is dedicated to developing ethical and environmentally friendly products for human health, has successfully developed a number of food technology prototypes using its precision synthesis and fermentation platforms new generation.
Among them is the ability to produce ingredients at low cost while leaving a low carbon footprint.
In addition, the company seeks partnerships and collaborations to implement new, scalable manufacturing methods for its customers’ products.
CB Therapeutics’ solutions, as a hub of innovation, have also enabled it to rapidly expand its intellectual property portfolio into highly competitive areas such as psychedelics and cannabinoid biosynthesis, bioinformatics and other technologies.
Dr. Jacob Vogan, CSO of CB Therapeutics, said JoyNews‘ Mahmud Mohammed-Nurudeen via Zoom that the biotechnology company has developed a powerful, fast and portable platform to generate a wide range of ingredients and products.
According to Dr. Vogan, the company has a strong track record in nutraceutical and clinical research due to its work in cannabinoid and psychedelic medicine.
He said the platform can solve even broader supply chain problems in a sustainable way.
CB Therapeutics has used scalable precision fermentation to create proteins, fats, colors, flavors, aromas and more in the lab.
According to CEO Sher Ali Butt, this is an exciting time for biotechnology and biomanufacturing.
Butt said the company has the people and equipment to produce bioidentical, animal-free proteins, peptides, fats, flavors and vitamins traditionally found in animal foods. animal origin.
The company’s process also improves products, such as allergen-reducing proteins and peptides, or enrichment products with vitamins, antioxidants and other health-promoting nutrients.
CB Therapeutics is enthusiastic about alternative animal products, which include alternatives to dairy, meat and seafood.
Other food technologies the company is passionate about include nutrient and flavor enriched food products, cheese composition and associated microorganisms.
CB Therapeutics said its expertise in synthetic genomics and bioengineering has significantly advanced its proprietary microorganism, enzyme and production process production platform.
After more than four years of development, the CB Therapeutics team said they are proud to produce a wide range of phytochemicals faster, with fewer resources, at higher yields, and with greater purity, consistency, and efficacy. to those of competing platforms.
CB Therapeutics is based in Southern California, where it has a new fully licensed 16,000 square foot commercial lot facility.